NKTR Related Analyst Ratings
-
Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR)
-
Hapoalim Securities Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Ongoing Programs to Help Drive Share Price
-
BMO Capital Upgrades Nektar Therapeutics (NKTR) to Outperform
-
Morgan Joseph Reiterates a 'Buy' on Nektar Technology (NKTR); Sees Substantial Added Value From AstraZeneca Deal
-
Wedbush Morgan Maintains an 'Outperform' on Nektar Therapeutics (NKTR); Raises Price Target
-
Boenning & Scattergood Starts Nektar (NKTR) at Outperform
-
Brean Murray Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Expect Substantial Value Creation Through Partnerships
-
Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR); Partner Momentum Building
-
William Blair & Co Initiates Coverage on Nektar Therapeutics (NKTR) with an Outperform; Near-term Positive Catalysts
-
Morgan Joseph Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; PEG Technology & Pipeline Orchestrating Strong Comeback
-
Matrix USA Rating Changes 9/5
-
Matrix USA Rating Changes 7/25
-
Matrix USA Rating Changes 5/21
-
Matrix USA Rating Changes 5/8
-
Matrix USA Rating Changes 5/6
-
Matrix USA Rating Changes 4/17
-
Matrix USA Rating Changes 4/10
-
Piper Jaffray Downgrades MannKind (MNKD) to Neutral; Slashes PT from $19 to $1.50
-
Pacific Growth Downgrades Nektar Therapeutics (NKTR) to Neutral
-
Merrill Lynch Downgrades Nektar (NKTR) and MannKind (MNKD)
-
Matrix USA Rating Changes 4/2
-
Matrix USA Rating Changes 11/15
-
Matrix USA Rating Changes 11/14
-
Nektar Therapeutics (Nasdaq: NKTR) Bull and Bear Story
-
Nektar Therapeutics (NKTR): Pfizer continues to be serious about Exubera
-
Morgan Stanley upgrades Nektar Therapeutics (NKTR) to Equal Weight
-
WR Hambrecht Said Pfizer (PFE) May Buy Nektar (NKTR) Following Torcetrapib Blow-Up
-
Morgan Stanley downgrades Nektar Therapeutics (NKTR) to Underweight
-
Miller Johnson upgrades Nektar Therapeutics (NKTR) to Outperform
-
Morgan Stanley upgrades Nektar Therapeutics (NKTR) to Equal Weight
-
Oppenheimer Starts Nektar Therapeutics (NKTR) at Buy
-
WR Hambrecht Says NBIX Blow-Up Could Benefit Nektar (NKTR)
-
Jim Cramer Positive on Nektar Therapeutics (NKTR)
-
WR Hambrecht Sees Short Squeeze Coming in Nektar Therapeutics (NKTR)
-
WR Hambrecht Positive on NKTR
-
Morgan Stanley downgrades NKTR to Underweight
-
WR Hambrecht and Piper Expect US Approval for Exubera Tomorrow
-
WR Hambrecht on NKTR After Pfizer Buys Sanofi's Rights to Exubera
-
NKTR Higher Ahead of Expected EU Exubera Opinion
-
Piper Jaffray Expects Exubera to Be Approved in Nov
-
Morgan Stanley Starts NKTR at Equal-Weight
-
Pacific Growth downgrades NKTR to Equal-Weight
-
WR Hambrecht Starts NKTR at Buy
-
Lehman Brothers Upgrades NKTR to Overweight
-
NKTR started at Buy at Soleil Securities
Back to NKTR Stock Lookup
